University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan
The University of Michigan Comprehensive Cancer Center (UMCCC) was founded in 1986. UMCCC received its NCI designation as a cancer center in 1988 and its comprehensive designation in 1991. The Center is also a founding member of the National Comprehensive Cancer Network, a consortium of 25 of the nation's premier centers, which develops national guidelines for the delivery of effective, quality care.
UMCCC’s mission is the conquest of cancer through innovation and collaboration. As part of the University of Michigan Health System, the center unites nearly 400 scientists and clinicians in multidisciplinary teams devoted to cancer research and patient care. UMCCC is home to 22 basic, clinical/translational, and population sciences programs.
Laboratory research is conducted in six basic research programs: cancer cell biology, cancer genetics, molecular imaging, experimental therapeutics, radiation sciences, and tumor immunology/ host response.
Clinical research includes a focus on bladder cancer, breast oncology, childhood cancers, connective tissue, cutaneous oncology, endocrine oncology, gastrointestinal oncology, gynecologic oncology, head and neck oncology, hematologic malignancies/bone marrow transplantation, neuro-oncology, prostate cancer, psych-oncology and thoracic oncology.
Cancer population sciences is divided into biomedical prevention and socio-behavioral research. In addition, UMCCC has a strong focus on outcomes, disparities and quality of life research. Efforts include understanding how breast cancer patients make treatment decisions, assessing the economic impact of cancer treatment, and examining the geographic variations in surgical options.
UMCCC researchers are at the forefront of precision medicine. A program called Mi-OncoSeq uses high-throughput gene sequencing techniques developed and studied in the university’s laboratories. Through informed consent, patients with metastatic or refractory cancer for whom standard therapies are not effective can be evaluated. This multidisciplinary project brings together a Precision Medicine Tumor Board with expertise from clinical oncology, clinical genetics, genomic science/bioinformatics, clinical pathology, social and behavior sciences, and bioethics. It uses gene sequencing results to give clinicians and patients recommendations regarding clinical trials or targeted therapy based on the molecular characteristics of an individual patient’s cancer. Researchers also use the data to identify new genetic anomalies.
UMCCC members engaged in research come from more than 40 departments across 12 University of Michigan schools, including Medicine, Public Health, Nursing, Engineering, Dentistry, Social Work, Information and Pharmacy. The university’s North Campus Research Complex provides a unique 174-acre campus near the Medical Center and adjacent to the College of Engineering, where UMCCC members from multiple schools collaborate in both wet and dry labs to conduct innovative research integrating multiple disciplines.
The University of Michigan is among the largest clinical enterprises in cancer. Patients meet with multidisciplinary teams in one of 17 multidisciplinary and 10 specialty clinics, organized by cancer type. In each of these clinics, specialized physicians, including dedicated pathologists and radiologists, collaborate to provide comprehensive care for each patient. The center’s teams of physicians and nurses work with colleagues in local communities to provide ongoing care for cancer patients and their families. Risk evaluations, genetic counseling, and fertility counseling are also provided.
* This profile was provided by the University of Michigan Comprehensive Cancer Center.